News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Optinose Inc
(NQ:
OPTN
)
0.6990
+0.0190 (+2.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Optinose Inc
< Previous
1
2
3
4
5
Next >
OptiNose's Return On Capital Employed Insights
March 09, 2023
Via
Benzinga
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Earnings Preview: OptiNose
March 06, 2023
Via
Benzinga
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
February 28, 2023
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023
From
Optinose, Inc.
Via
GlobeNewswire
OptiNose: Q2 Earnings Insights
August 11, 2022
OptiNose (NASDAQ:OPTN) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Optinose Announces CEO Transition and Business Update
January 31, 2023
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
December 15, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Departure of Acting Chief Financial Officer
December 09, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 11, 2022
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
Optinose Shared Additional Encouraging Data From Late-Stage Chronic Sinusitis Studies
July 08, 2022
Via
Benzinga
Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial
June 13, 2022
Via
Benzinga
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
November 30, 2022
From
Optinose, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
November 25, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 24, 2022
Via
Benzinga
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
November 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 21, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 21, 2022
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Via
InvestorPlace
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
November 10, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
November 09, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
November 07, 2022
Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time
From
Optinose, Inc.
Via
GlobeNewswire
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
October 21, 2022
From
Optinose, Inc.
Via
GlobeNewswire
Pooled Data Show Optinose's XHANCE Cut Sinusitis Flares By 66%
July 13, 2022
Optinose Inc (NASDAQ: OPTN) announced the results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for chronic sinusitis.
Via
Benzinga
Looking Into OptiNose's Return On Capital Employed
June 16, 2022
Benzinga Pro data, OptiNose (NASDAQ:OPTN) reported Q1 sales of $14.76 million. Earnings fell to a loss of $25.33 million, resulting in a 62.14% decrease from last quarter.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 15, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 13, 2022
Via
Benzinga
71 Biggest Movers From Yesterday
June 16, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration...
Via
Benzinga
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
70 Stocks Moving In Monday's Mid-Day Session
June 13, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.